However, a meta-analysis of sixteen studies comprising of 5,697 breast cancer cases showed, recently, that CD24 overexpression was significantly associated with shortened overall survival, while no such association was observed between CD44 and CD44+/CD24- phenotypes, suggesting a large-scale study is necessary to confirm these findings [24]. The gene discussed is CD44; the disease is breast carcinoma.